Physician profile
Kayvan Keyhani
NPI 1275549552
$13,023.30
in general payments reported to CMS, 2019-2025
32 companies · $1,796 in 2025
The $1,796 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $458 · 2021: $1,926 · 2022: $2,599 · 2023: $3,922 · 2024: $1,329 · 2025: $1,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,538 · Honoraria: $1,500 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,538.19 |
| Honoraria | $1,500.00 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $4,333.87 | 2021-2023 | |
| Alcon Vision LLC | $1,561.08 | 2019-2025 | Clareon, Hydrus Microstent, Tryptyr |
| Bausch & Lomb Americas INC. | $854.04 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $646.67 | 2020-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $627.65 | 2020-2025 | Acthar |
| Glaukos Corporation | $561.42 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Aerie Pharmaceuticals, INC. | $471.00 | 2019-2021 | |
| Oyster Point Pharma, INC. | $417.85 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $358.77 | 2019-2025 | Tecnis Iol, Tecnis Iol |
| Rxsight INC | $339.26 | 2023-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Abbvie INC. | $295.86 | 2022-2025 | |
| Horizon Therapeutics Plc | $277.36 | 2019-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $258.00 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $248.76 | 2019-2021 | |
| Coopervision INC. | $240.95 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $219.20 | 2019-2023 | |
| Allergan, INC. | $207.34 | 2019-2022 | |
| Amgen INC. | $194.63 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $188.83 | 2020-2024 | Omni Surgical System, Tearcare System |
| Kala Pharmaceuticals, INC. | $133.78 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $119.97 | 2021-2022 | |
| Dompe US, INC. | $95.55 | 2021-2024 | Oxervate |
| Astellas Pharma US INC | $65.38 | 2024 | Izervay |
| Biotissue Holdings INC. | $61.21 | 2022-2025 | |
| Mallinckrodt Enterprises LLC | $56.53 | 2019 | |
| Harrow Eye, LLC | $43.03 | 2024 | Flarex, Tobradex St |
| Shire North American Group INC | $42.46 | 2019 | |
| Thea Pharma INC. | $34.54 | 2023-2024 | Iyuzeh |
| Ivantis, INC | $20.70 | 2021 | |
| Rayner Intraocular Lenses Limited | $18.73 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $15.17 | 2021 | |
| Optos, INC. | $13.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayvan Keyhani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.